The value of adjuvant chemotherapy in elderly patients has been the subject of many
overviews, with opinions varying from “not effective”, since randomized trials have not been …

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Introduction: Colon cancer is common and can be considered a disease of older adults with
more than half of cases diagnosed in patients aged over 70 years. Decision-making about …

Background Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based
adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection …

PURPOSE A number of studies suggest that older patients may have reduced or no benefit
from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III …

Background Selecting elderly people with colorectal cancer (CRC) for adjuvant
chemotherapy is challenging. Comprehensive geriatric assessment (CGA) can help by …

Background: The benefit of chemotherapy in colon cancer patients is well documented but
depends largely on whether patients complete the planned treatment regimen. We …

Background Factors that are prognostic of early discontinuation of adjuvant chemotherapy
among stage III colon cancer patients have yet to be described. To address this gap, a …

The aim of this study is to investigate the effects of CAPOX and capecitabine on recurrence‐
free survival (RFS) and overall survival (OS) among elderly stage III colon cancer patients …

Neoadjuvant radiotherapy previous to radical surgery, both as short-course radiotherapy
and as long-course radiotherapy combined with 5-FU-based chemotherapy (LCRCT), is …